BridgeBio: Musculoskeletal Diseases trials

The registry lists 10 Musculoskeletal Diseases studies with BridgeBio as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 2 5Phase 3 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 2
• Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)RecruitingNCT07169279Phase 2
• An Interventional Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT06873035Phase 2/3
• Prospective Clinical Assessment Study in Children With HypochondroplasiaRecruitingNCT06410976
• Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 2
• A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedNCT06164951Phase 3
• Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Active, not recruitingNCT05680818Phase 3
• ADH1 and ADH2 Disease Monitoring Study (DMS)Active, not recruitingNCT05227287
• Study of Infigratinib in Children With AchondroplasiaCompletedNCT04265651Phase 2
• Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)CompletedNCT04035811